|
**Overview**: Deep Vein Thrombosis Panel**Introduction**: The Deep Vein Thrombosis Panel is a diagnostic tool designed to screen for deep vein thrombosis using plasma samples. In India, DVT/PE incidence is rising (~1-2 per 1,000 hospital admissions), with risk factors including prolonged immobility, surgery, cancer, pregnancy, and thrombophilia (Factor V Leiden, protein C/S deficiency, antiphospholipid syndrome). High morbidity from underdiagnosis in rural/low-SES patients, limited Doppler access, delayed anticoagulation leading to pulmonary embolism or post-thrombotic syndrome. Per hematology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs coagulation analyzer for PT, aPTT, INR, D-dimer, protein C/S, antithrombin III, lupus anticoagulant, Factor V Leiden over 1-2 days with high accuracy, valuable for risk stratification and exclusion of DVT. This diagnostic falls under thrombophilia screening and targets patients with leg swelling, pain, or high-risk factors, addressing accurate detection to guide Doppler and anticoagulation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing thromboembolic events. Its plasma-based approach ensures reliable coagulation assessment.**Other Names**: DVT Pnl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: D-dimer and thrombophilia panel standard; in India, used in VTE protocols.**Purpose**: The test screens for 9 parameters including D-dimer and thrombophilia markers to guide DVT assessment, exclude thrombosis, inform prophylaxis.**Test Parameters**: 1. PT, 2. aPTT, 3. INR, 4. D-Dimer, 5. Protein C, 6. Protein S, 7. Antithrombin III, 8. Lupus Anticoagulant, 9. Factor V Leiden.**Pretest Condition**: No fasting required; patients should report leg swelling, pain, or risk factors.**Specimen**: 3 mL plasma in 1 NaCit tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on swelling, travel, surgery, pregnancy, family thrombosis history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated DVT including PE, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using coagulation analyzer by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate thrombophilia or active thrombosis risk, necessitating specialist input. Normal D-dimer may exclude DVT.**Specialist Consultation**: Hematologists or vascular specialists should be consulted for management.**Additional Supporting Tests**: Doppler ultrasound, Wells score for confirmation.**Test Limitations**: D-dimer nonspecific; comprehensive approach required.**References**: Indian Journal of Hematology 2024, VTE Studies India 2023. |
